Drug intelligence / Profile preview

YKST07

Development stage: Preclinical
Lead developer: Excyte Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YKST07 is a preclinical-stage bispecific antibody being developed by Excyte Biopharma. As of early 2024, the specific molecular targets and primary therapeutic indications for YKST07 have not been publicly disclosed by the developer. It is part of Excyte Biopharma's pipeline which focuses on multi-specific antibodies (bispecific and trispecific) for the treatment of hematological malignancies and solid tumors. The drug is currently undergoing early-stage preclinical evaluation.

Beyond the preview

Go deeper on YKST07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YKST07.

Explore the full profile